Literature DB >> 2130734

Effects of neonatal screening for cystic fibrosis on reproduction, attitudes toward reproductive behaviour and genetic knowledge.

J E Dankert-Roelse1, K Knol, L P ten Kate.   

Abstract

An evaluation was carried out into whether neonatal screening for Cystic Fibrosis could potentially prevent the birth of more affected children in the same family. Although CF was detected in more than 50% within the first year of life in those cases where a diagnosis was made on clinical symptoms, in these families 10 children -- among whom two with CF -- were born prior to the CF diagnosis. With neonatal screening, no pregnancies were started before the CF-diagnosis. No differences were found in attitudes toward further reproduction and understanding of important genetic facts. Although prenatal diagnosis was not yet possible at the time of the study, approximately 50% of the parents showed a positive attitude toward this option. Minimizing the delay in diagnosis by neonatal screening, together with the availability of prenatal diagnosis may lead to a significant reduction in subsequent births of CF cases.

Entities:  

Mesh:

Year:  1990        PMID: 2130734

Source DB:  PubMed          Journal:  Acta Univ Carol Med (Praha)        ISSN: 0001-7116


  3 in total

1.  Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.

Authors:  E Ranieri; B D Lewis; R L Gerace; R G Ryall; C P Morris; P V Nelson; W F Carey; E F Robertson
Journal:  BMJ       Date:  1994-06-04

Review 2.  The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review.

Authors:  Stuart J Wright; Cheryl Jones; Katherine Payne; Nimarta Dharni; Fiona Ulph
Journal:  Appl Health Econ Health Policy       Date:  2015-12       Impact factor: 2.561

3.  Parental decision-making and acceptance of newborn bloodspot screening: an exploratory study.

Authors:  Stuart G Nicholls; Kevin W Southern
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.